PT  - JOURNAL ARTICLE
AU  - BALÁZS NÉMETH
AU  - ISTVÁN KISS
AU  - IVÁN PÉTER
AU  - ZÉNÓ AJTAY
AU  - ÁDÁM NÉMETH
AU  - LÁSZLÓ MÁRK
AU  - ATTILA CSORBA
AU  - TAMÁS KŐSZEGI
AU  - DIÁNA MÜHL
AU  - PÉTER KUSTÁN
TI  - Monitoring of L-Arginine and Endogenous Dimethylarginines in Survivor Septic Patients – A Pilot Study
DP  - 2016 Sep 01
TA  - In Vivo
PG  - 663--669
VI  - 30
IP  - 5
4099  - http://iv.iiarjournals.org/content/30/5/663.short
4100  - http://iv.iiarjournals.org/content/30/5/663.full
SO  - In Vivo2016 Sep 01; 30
AB  - Background/Aim: Nitric oxide (NO) pathway plays a major role in the development and advancement of inflammation. We aimed to design a study and investigate its feasibility to show the changes of L-arginine, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA), which are important regulators of the NO pathway. Patients and Methods: Concentrations of L-arginine, ADMA and SDMA were measured by liquid chromatography-tandem mass spectrometry. Seventeen septic survival patients were enrolled and blood samples were obtained on the first, third and fifth day after the diagnosis of sepsis. Sixteen non-septic matched controls were recruited. Results: ADMA levels on admission correlated well with sequential organ failure assessment (SOFA) score. During the follow-up, L-arginine/ADMA ratio increased significantly from day 1 to day 3 (p=0.005), then decreased from day 3 to day 5 (p=0.023). Conclusion: This study design seems feasible to investigate changes of L-Arginine, ADMA and SDMA in sepsis survival patients.